Stock ALNY ALNYLAM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Real-time Estimate Cboe BZX
Other stock markets
 11:10:13 2024-05-07 am EDT 		5-day change 1st Jan Change
153.3 USD +1.36% Intraday chart for Alnylam Pharmaceuticals, Inc. +5.68% -20.52%
03:13pm HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating MT
May. 02 Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating
MT
Alnylam Issues 2023 Corporate Responsibility Report
BU
Alnylam Pharmaceuticals : 2023 REPORT
PU
Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed
MT
Alnylam Pharmaceuticals : Q1 2024 GAAP/Non-GAAP Reconciliation ›
PU
Transcript : Alnylam Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (ALNY) ALNYLAM PHARMACEUTICALS Posts Q1 Revenue $494.3M, vs. Street Est of $426.9M
MT
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Alnylam: Q1 Earnings Snapshot
AQ
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
BU
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024
CI
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
PR
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia
CI
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
BU
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
MT
Sector Update: Health Care
MT
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
AQ
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint
MT
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower...
Our Logo
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALNY Stock
  4. News Alnylam Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW